The FDA on July 24, 2020 granted accelerated approval to TECARTUSĀ® (brexucabtagene autoleucel), a CD19-directed genetically modified Autologous T cell immunotherapy, for the treatment of adult patients with relapsed or refractory Mantle Cell Lymphoma (MCL). TECARTUSĀ® is a product of Kite Pharma, a subsidiary of Gilead Sciences.
Other Pages – Bottom Ad
Advertisement
Subscribe
